Healthcare Industry News: HSMN NewsFeed
News Release - October 27, 2010
Eighth CyberKnife System in South Korea Installed and Treating PatientsInstallation at Korea Cancer Care Hospital Marks First Hospital in Asia with Two CyberKnife Systems in Use
SUNNYVALE, Calif., Oct. 27 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (Nasdaq:ARAY ), a global leader in the field of radiosurgery, today announced that the Korea Cancer Care Hospital (KCCH) in Seoul, South Korea has installed its second CyberKnife® Robotic Radiosurgery System, marking the first hospital in the country – and Asia – to have two CyberKnife Systems in use.
The recently acquired CyberKnife System is located at the Asia Cancer Center (ACC), the new cancer hospital of KCCH located in Busan. It represents the eighth CyberKnife System in South Korea and the country's first equipped with a linear accelerator capable of delivering a dose rate of 1,000MU (monitor unit) per minute, which improves the system's efficiency.
"We are very pleased to be the first hospital in South Korea with two CyberKnife Systems in use," said Dr. Kwang Mo Yang, Chief of Cancer Research Division and Radiation Oncologist at ACC. "The CyberKnife System, a state-of-the-art form of cancer care will enable us to expand our radiation offerings to patients who may not have been able to tolerate other treatments or have medically or surgically inoperable tumors. With this additional capability at ACC, the CyberKnife System is a definite asset for our treatment program, offering an alternative to our patients and establishing the ACC's role as 'The First Medical Hub of Asia.'"
"We are very proud that the CyberKnife System has been serving Korean patients and KCCH, one of the most prestigious cancer care and research institutes, for eight years," said Cynthia Chan, Director of Marketing, Accuray APAC. "CyberKnife technology is increasingly accepted by the medical community in Korea. The second CyberKnife System with the newest product enhancements now being used at ACC not only broadens patient access, but also contributes to the clinical development of radiosurgery and high precision radiotherapy in Korea."
Korea Cancer Care Hospital has been one of the nation's leading cancer centers for over four decades. In 2002, KCCH installed their first CyberKnife System and established their medical complex composed of a hospital, research center, and the national radiation emergency medical center. Today, the second CyberKnife System installed treating patients at ACC, the KCCH's Busan branch, will help to play an important role in enhancing medical welfare, improving research of radiation medicine, and providing world class treatment.
About Asia Cancer Center
ACC is a 300 bed facility offering a specialized cancer prevention center, research center and radiation emergency medical center. ACC intends to offer facilities such as a sea park, resort and golf course with the vision to establish "The First Medical Hub of Asia" offering tourism, recuperation and treatment all in one place. ACC will establish ten cancer sub-centers specializing in stomach, lung, liver, colorectal, breast, cervical and thyroid cancers, as well as clinical service center and cancer prevention center. A series of sensitivity treatments such as psychology, languages, fine arts and ceramic arts will also be provided to assist in the complete rapid recovery of patients.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq:ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 100,000 treatments worldwide and currently more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to multiple units, patient treatment volumes, clinical acceptance, clinical benefits and investments in radiosurgery are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission filed on August 31, 2010. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsNew Data Reinforce Benefits of TomoTherapy(R) Platform for Mainstream Radiation Therapy Treatment Indications
CyberKnife(R) System Provides Effective Treatment Option with Minimal Side Effects and Excellent Cosmesis for Early Stage Breast Cancer Patients
First Cancer Patients in Africa Treated with the TomoTherapy(R) System